UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

September 11, 2020

 

001-36686

(Commission file number)

 

Forward Pharma A/S

(Translation of registrant’s name into English)

 

Østergade 24A, 1st Floor

1100 Copenhagen K, Denmark

(Address of principal executive office)

 

________________________________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F [ X ] Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes [  ] No [ X ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes [  ] No [ X ]

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [  ] No [ X ]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

 

Item 1. Other Items

 

Forward Pharma A/S (the “Company”) is submitting this Report on Form 6-K to provide its (i) interim condensed consolidated statement of financial position as of June 30, 2020, unaudited, and December 31, 2019 and (ii) unaudited interim condensed consolidated statements of profit or loss for each of the six-month periods ended June 30, 2020 and 2019, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. Exhibits 99.1 and 99.2 are furnished herewith solely for the purpose of meeting the requirements of Nasdaq Stock Market Rule 5250(c)(2) to submit an interim balance sheet and income statement as of the end of the Company’s second quarter.

 

EXHIBIT INDEX

 

 

	Exhibit No.	Description
	99.1*	Interim condensed consolidated statement of Financial Position of the Company as of June 30, 2020, unaudited, and December 31, 2019
	99.2*	Unaudited interim condensed consolidated statement of Profit or Loss of the Company for each of the six-month periods ended June 30, 2020 and 2019

 

*

Furnished herewith solely for the purpose of meeting the requirements under Nasdaq Stock Market Rule 5250(c)(2) in connection with submission of an interim balance sheet and income statement as of the end of its second quarter.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Date:  September 11, 2020	Forward Pharma A/S
	By:	/s/ Claus Bo Svendsen
		Name:  Claus Bo Svendsen
		Title:    Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 99.1

 

Interim Condensed Consolidated Statement of Financial Position

 

as of June 30, 2020, Unaudited, and December 31, 2019

 

Assets

 

		June 30, 2020 (Unaudited)				December 31, 2019
		USD `000				USD `000
Non-current Assets:
Other non-current assets			3				2
Total non-current assets			3				2
Prepaid expenses			128				292
Other receivables			187				95
Income tax receivable			179				178
Cash and cash equivalents			75,626				77,598
Total current assets			76,120				78,163
Total assets			76,123				78,165

 

Equity and Liabilities

 

		June 30, 2020 (Unaudited)				December 31, 2019
		USD `000				USD `000
Share capital			154				152
Other components of equity:
Foreign currency translation reserve			86,065				85,849
Accumulated deficit			(10,738	)			(8,432	)
Equity attributable to shareholders of the Parent			75,481				77,569
Total equity			75,481				77,569
Trade payables			165				82
Accrued liabilities			477				514
Total current liabilities			642				596
Total equity and liabilities			76,123				78,165

 

 

 

 

 

Exhibit 99.2

 

Unaudited Interim Condensed Consolidated Statement of Profit or Loss

 

for the six-month periods ended June 30, 2020 and 2019

 

amounts in thousands except per share amounts

 

		Six Months Ended June 30,
		2020				2019
		USD				USD
Research and development costs			(235	)			(626	)
General and administrative costs			(1,788	)			(2,602	)
Operating loss			(2,023	)			(3,228	)
Foreign exchange rate (loss) gain			(240	)			187
Other finance income, net			4				191
Net loss for the period			(2,259	)			(2,850	)
Net loss for the period attributable to:
Equity holders of the Parent			(2,259	)			(2,850	)
Net loss per share basic and diluted			(0.02	)			(0.03	)